Abouzar Bagheri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Abouzar Bagheri has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Zahra-Soheila Soheili
Department of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
8 shared publications - Mohammad Amin Khazeei Tabari
Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Mazandaran, Iran
6 shared publications Hamid Ahmadieh
Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 shared publicationsMohammad Amir Mishan
Ocular Tissue Engineering Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran
5 shared publications- Mozhgan Rezaei Kanavi
Ocular Tissue Engineering Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran
5 shared publications Shahram Samiei
Blood Transfusion Research Centre High Institute for Research and Education in Transfusion, Medicine, Tehran, Iran
5 shared publications
Latest Publications
- 23 October 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (3) , 3335-3352
Critical regulatory roles of non-coding RNAs in driving cancer sensitivity to Carmustine: a systematic review
Cancer is a significant health burden throughout the world. Gliomas are a type of cancer with the origin of central nervous system. They are the most prevalent group of brain malignancies. Chemotherapy is an integral component of standard treatment strategies for this disease. Carmustine is regarded as one of the most effective chemotherapy drugs against different cancer types and, most importantly, Gliomas. However development of resistance to Carmustine has restricted its application. It is evidenced that non-coding RNAs, especially microRNAs (miRNAs, miRs), play significant roles in association with the occurrence of this phenomenon. In the present systematic study, the interaction mechanisms between non-coding RNAs And Carmustine in the modulation of sensitivity to this drug in cancer have been investigated. The search and analysis steps followed PRISMA guidelines. A comprehensive search was conducted across databases including PubMed, Scopus, and Web of Science. According to the opted criteria, a total of 12 studies were eligible for inclusion in the study. Up or downregulation of non-coding RNA expression levels effectively influences the biology of various signaling pathways in Glioblastoma cell lines or tumors. Eventually, these significant influences would be translated into an altered status of sensitivity to Carmustine. A deeper understanding of the underscored network of interactions could be potentially helpful for improving the efficacy of chemotherapy-based approaches against cancer.
- 23 October 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (3) , 3335-3352
Critical regulatory roles of non-coding RNAs in driving cancer sensitivity to Carmustine: a systematic review
Cancer is a significant health burden throughout the world. Gliomas are a type of cancer with the origin of central nervous system. They are the most prevalent group of brain malignancies. Chemotherapy is an integral component of standard treatment strategies for this disease. Carmustine is regarded as one of the most effective chemotherapy drugs against different cancer types and, most importantly, Gliomas. However development of resistance to Carmustine has restricted its application. It is evidenced that non-coding RNAs, especially microRNAs (miRNAs, miRs), play significant roles in association with the occurrence of this phenomenon. In the present systematic study, the interaction mechanisms between non-coding RNAs And Carmustine in the modulation of sensitivity to this drug in cancer have been investigated. The search and analysis steps followed PRISMA guidelines. A comprehensive search was conducted across databases including PubMed, Scopus, and Web of Science. According to the opted criteria, a total of 12 studies were eligible for inclusion in the study. Up or downregulation of non-coding RNA expression levels effectively influences the biology of various signaling pathways in Glioblastoma cell lines or tumors. Eventually, these significant influences would be translated into an altered status of sensitivity to Carmustine. A deeper understanding of the underscored network of interactions could be potentially helpful for improving the efficacy of chemotherapy-based approaches against cancer.
- 13 September 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (11) , 1-16
Non-coding RNAs’ pivotal importance in modulation of cancer sensitivity to Topotecan: a systematic review
Cancer is one of the leading causes of mortality worldwide. Development of new methods or improving the efficiency of already existing methods is essential in the successful treatment of this disease. Topotecan, a chemotherapeutic drug, has been used to inhibit various cancer types. However, chemotherapy resistance to this drug in cancer has impeded its maximum performance. miRNAs and other non-coding RNAs play crucial roles in regulating this attribute. In this systematic review, we investigated the interaction mechanism between these molecules and Topotecan in the modulation of cancer sensitivity to this agent. This study was carried out according to PRISMA guidelines. PubMed, Scopus, and Web of Science databases were comprehensively searched, using our predefined search terms. Following a selective process based on strategic criteria, eleven studies were included in the analysis. Altered expression levels of non-coding RNAs, especially miRNAs, regulated the sensitivity of cancer cell lines and animal models, directly and indirectly, through affecting cascades of signaling molecules. This impact was recorded in a variety of cancer types, including retinoblastoma, renal cell carcinoma, colorectal cancer, cervical cancer, breast cancer, prostate cancer, and leukemia. The highlighted interactions potentially offer new opportunities for modifying therapeutic intervention utilizing chemotherapeutic agents.
- 13 September 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (11) , 1-16
Non-coding RNAs’ pivotal importance in modulation of cancer sensitivity to Topotecan: a systematic review
Cancer is one of the leading causes of mortality worldwide. Development of new methods or improving the efficiency of already existing methods is essential in the successful treatment of this disease. Topotecan, a chemotherapeutic drug, has been used to inhibit various cancer types. However, chemotherapy resistance to this drug in cancer has impeded its maximum performance. miRNAs and other non-coding RNAs play crucial roles in regulating this attribute. In this systematic review, we investigated the interaction mechanism between these molecules and Topotecan in the modulation of cancer sensitivity to this agent. This study was carried out according to PRISMA guidelines. PubMed, Scopus, and Web of Science databases were comprehensively searched, using our predefined search terms. Following a selective process based on strategic criteria, eleven studies were included in the analysis. Altered expression levels of non-coding RNAs, especially miRNAs, regulated the sensitivity of cancer cell lines and animal models, directly and indirectly, through affecting cascades of signaling molecules. This impact was recorded in a variety of cancer types, including retinoblastoma, renal cell carcinoma, colorectal cancer, cervical cancer, breast cancer, prostate cancer, and leukemia. The highlighted interactions potentially offer new opportunities for modifying therapeutic intervention utilizing chemotherapeutic agents.
- Open Access
- 26 May 2025
- Published by Lyceum Publisher (Pvt) Ltd in PHYTONutrients
- p. 28-43
MicroRNAs in the anti-cancer effects of Ginsenosides: A Systematic Review
This systematic review highlights the pivotal functions of ginsenosides in cancer treatment through miRNA regulation. Ginsenosides, bioactive herbal compounds derived from ginseng, exhibit significant anti-cancer properties through mechanisms including inhibition of cell proliferation, epithelial-to-mesenchymal transition (EMT), metastasis, invasion, and induction of autophagy and apoptosis. MicroRNAs (miRNAs), small non-coding RNAs, play critical roles in gene regulation and have emerged as potential diagnostic, prognostic, and therapeutic targets in various cancers. Ginsenosides influence miRNA expression, underexpressing oncogenic miRNAs and overexpressing tumor suppressor miRNAs, thereby exerting their anti-cancer effects. The literature review covered studies from 2011 to 2021 sourced from PubMed, Scopus, Cochrane Library, and Web of Science, adhering to the PRISMA guidelines. Eligible studies were screened, resulting in the selection of 26 preclinical studies. These studies demonstrate that ginsenosides modulate the expression of various miRNAs, contributing to anti-tumorigenic activities across different cancer types, including glioma, non-small cell lung cancer, breast cancer, acute leukemia, hepatocellular carcinoma, ovarian cancer, medulloblastoma, prostate cancer, liver cancer, oral squamous cell carcinoma, retinoblastoma, and gallbladder cancer. By influencing miRNA pathways, ginsenosides can inhibit tumor growth, migration, invasion, and induce apoptosis, highlighting their therapeutic potential in oncology.
- 26 May 2025
- Published by Lyceum Publisher (Pvt) Ltd in PHYTONutrients
- p. 28-43
Open AccessMicroRNAs in the anti-cancer effects of Ginsenosides: A Systematic Review
This systematic review highlights the pivotal functions of ginsenosides in cancer treatment through miRNA regulation. Ginsenosides, bioactive herbal compounds derived from ginseng, exhibit significant anti-cancer properties through mechanisms including inhibition of cell proliferation, epithelial-to-mesenchymal transition (EMT), metastasis, invasion, and induction of autophagy and apoptosis. MicroRNAs (miRNAs), small non-coding RNAs, play critical roles in gene regulation and have emerged as potential diagnostic, prognostic, and therapeutic targets in various cancers. Ginsenosides influence miRNA expression, underexpressing oncogenic miRNAs and overexpressing tumor suppressor miRNAs, thereby exerting their anti-cancer effects. The literature review covered studies from 2011 to 2021 sourced from PubMed, Scopus, Cochrane Library, and Web of Science, adhering to the PRISMA guidelines. Eligible studies were screened, resulting in the selection of 26 preclinical studies. These studies demonstrate that ginsenosides modulate the expression of various miRNAs, contributing to anti-tumorigenic activities across different cancer types, including glioma, non-small cell lung cancer, breast cancer, acute leukemia, hepatocellular carcinoma, ovarian cancer, medulloblastoma, prostate cancer, liver cancer, oral squamous cell carcinoma, retinoblastoma, and gallbladder cancer. By influencing miRNA pathways, ginsenosides can inhibit tumor growth, migration, invasion, and induce apoptosis, highlighting their therapeutic potential in oncology.
- Open Access
- 8 May 2025
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 39 (12) , e70049
Development and Validation of In‐House Conventional and Multiplex PCR Methods for the Detection and Identification of Lophomonas spp.: An Innovative Approach
Background: Pulmonary lophomoniasis is an emerging disease caused by the protozoan pathogen Lophomonas spp. Recently, a conventional polymerase chain reaction (PCR) method has been developed. However, its sensitivity and specificity remain to be fully established. Therefore, this study aimed to develop in‐house conventional and multiplex PCR for the detection and identification of Lophomonas infections. Additionally, we attempted to compare the diagnostic performance of these novel PCR tests with the current microscopic examination method using BAL samples.Methods: We studied 120 bronchoalveolar lavage (BAL) specimens of the patients clinically suspected of having lophomoniasis. The specimens were examined using three methods: microscopic examination (Giemsa staining), in‐house conventional PCR, and multiplex‐PCR. Moreover, multiplex‐PCR was used for the simultaneous identification of two species of Lophomonas.Results: Out of the 120 BAL specimens tested, 30 (25%) tested positive through microscopic wet mount examination. Among the three techniques, multiplex‐PCR was the most sensitive (100%, 95% CI, 88.3–100), while Giemsa staining had the lowest sensitivity (86.2%, 95% CI, 69.4–94.5). The data reveal a strong agreement between multiplex‐PCR and conventional PCR (κ = 0.96), while the lowest agreement was found between multiplex‐PCR and microscopy methods (κ = 0.16). The study also confirmed the presence of L. blattarum species in all samples using multiplex‐PCR.Conclusions: This study demonstrates that the in‐house multiplex‐PCR is a robust and accurate diagnostic test for the detection and identification of Lophomonas species. Therefore, our findings suggest that this method may be a powerful tool to overcome some diagnostic pitfalls for lophomoniasis.
- 8 May 2025
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 39 (12) , e70049
Open AccessDevelopment and Validation of In‐House Conventional and Multiplex PCR Methods for the Detection and Identification of Lophomonas spp.: An Innovative Approach
Background: Pulmonary lophomoniasis is an emerging disease caused by the protozoan pathogen Lophomonas spp. Recently, a conventional polymerase chain reaction (PCR) method has been developed. However, its sensitivity and specificity remain to be fully established. Therefore, this study aimed to develop in‐house conventional and multiplex PCR for the detection and identification of Lophomonas infections. Additionally, we attempted to compare the diagnostic performance of these novel PCR tests with the current microscopic examination method using BAL samples.Methods: We studied 120 bronchoalveolar lavage (BAL) specimens of the patients clinically suspected of having lophomoniasis. The specimens were examined using three methods: microscopic examination (Giemsa staining), in‐house conventional PCR, and multiplex‐PCR. Moreover, multiplex‐PCR was used for the simultaneous identification of two species of Lophomonas.Results: Out of the 120 BAL specimens tested, 30 (25%) tested positive through microscopic wet mount examination. Among the three techniques, multiplex‐PCR was the most sensitive (100%, 95% CI, 88.3–100), while Giemsa staining had the lowest sensitivity (86.2%, 95% CI, 69.4–94.5). The data reveal a strong agreement between multiplex‐PCR and conventional PCR (κ = 0.96), while the lowest agreement was found between multiplex‐PCR and microscopy methods (κ = 0.16). The study also confirmed the presence of L. blattarum species in all samples using multiplex‐PCR.Conclusions: This study demonstrates that the in‐house multiplex‐PCR is a robust and accurate diagnostic test for the detection and identification of Lophomonas species. Therefore, our findings suggest that this method may be a powerful tool to overcome some diagnostic pitfalls for lophomoniasis.
- 28 March 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- p. 1-18
The effects of flavonoid baicalein on miRNA expressions in cancer: a systematic review
Baicalein from Scutellaria baicalensis influences miRNA expression in various cancers, affecting key signaling pathways (PI3K/AKT, Wnt/β-catenin, mTOR) and processes like tumor growth, apoptosis, and metastasis. miRNAs, as small non-coding RNAs, play crucial roles in the cancer pathogenesis-associated gene regulations. This study is aimed at systematically reviewing the effects of baicalein on miRNA expression in various cancers. A comprehensive systematic review was conducted following PRISMA guidelines to investigate the impact of baicalein on miRNA expression in cancer. Databases including PubMed, Scopus, and Web of Science were systematically searched using key search terms. Inclusion criteria encompassed studies reporting changes in miRNA expression following baicalein treatment in cancer cell lines and animal models. Data extraction and risk of bias assessment based on SYRCLE’s risk of bias tool were performed to ensure methodological rigor and reliability of the findings. Fifteen studies meeting the inclusion criteria were included in the systematic review. Baicalein impacts miRNA expression in cancers like hepatocellular carcinoma, breast, cervical, ovarian, and gastric cancers, suggesting its potential as a multi-cancer therapeutic. Baicalein regulates tumor-related genes (HDAC10, MDM2, Bcl-2/Bax, and Cyclin E1) and signaling molecules (AKT, FOXO3α), affecting cell viability, apoptosis, and cell cycle, indicating targeted therapeutic potential. In vitro and in vivo studies show baicalein inhibits tumor growth, enhances apoptosis, and regulates cell proliferation, supporting its anticancer effects. Baicalein exhibits potential in modulating miRNA expression in cancer, offering avenues for therapeutic intervention. However, methodological rigor in future studies is essential to enhance the reliability and validity of findings. Comprehensive understanding of baicalein’s effects on miRNA expression holds promise for developing novel cancer treatment strategies.
- 28 March 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- p. 1-18
The effects of flavonoid baicalein on miRNA expressions in cancer: a systematic review
Baicalein from Scutellaria baicalensis influences miRNA expression in various cancers, affecting key signaling pathways (PI3K/AKT, Wnt/β-catenin, mTOR) and processes like tumor growth, apoptosis, and metastasis. miRNAs, as small non-coding RNAs, play crucial roles in the cancer pathogenesis-associated gene regulations. This study is aimed at systematically reviewing the effects of baicalein on miRNA expression in various cancers. A comprehensive systematic review was conducted following PRISMA guidelines to investigate the impact of baicalein on miRNA expression in cancer. Databases including PubMed, Scopus, and Web of Science were systematically searched using key search terms. Inclusion criteria encompassed studies reporting changes in miRNA expression following baicalein treatment in cancer cell lines and animal models. Data extraction and risk of bias assessment based on SYRCLE’s risk of bias tool were performed to ensure methodological rigor and reliability of the findings. Fifteen studies meeting the inclusion criteria were included in the systematic review. Baicalein impacts miRNA expression in cancers like hepatocellular carcinoma, breast, cervical, ovarian, and gastric cancers, suggesting its potential as a multi-cancer therapeutic. Baicalein regulates tumor-related genes (HDAC10, MDM2, Bcl-2/Bax, and Cyclin E1) and signaling molecules (AKT, FOXO3α), affecting cell viability, apoptosis, and cell cycle, indicating targeted therapeutic potential. In vitro and in vivo studies show baicalein inhibits tumor growth, enhances apoptosis, and regulates cell proliferation, supporting its anticancer effects. Baicalein exhibits potential in modulating miRNA expression in cancer, offering avenues for therapeutic intervention. However, methodological rigor in future studies is essential to enhance the reliability and validity of findings. Comprehensive understanding of baicalein’s effects on miRNA expression holds promise for developing novel cancer treatment strategies.
- Open Access
- 6 October 2024
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
Correction: Galbanic acid of Ferula assa-foetida L, as a regulator of the AMPK pathway in reduction of lipid accumulation in HepG2 cells
Correction: Galbanic acid of Ferula assa-foetida L, as a regulator of the AMPK pathway in reduction of lipid accumulation in HepG2 cells
- 6 October 2024
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
Open AccessCorrection: Galbanic acid of Ferula assa-foetida L, as a regulator of the AMPK pathway in reduction of lipid accumulation in HepG2 cells
Correction: Galbanic acid of Ferula assa-foetida L, as a regulator of the AMPK pathway in reduction of lipid accumulation in HepG2 cells
- 27 March 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-10
Detection of circulatory E. granulosus-derived cell-free DNA in the plasma and urine of human cystic echinococcosis using an in-house PCR: a potential promising diagnostic biomarker
Background The diagnostic tool for identifying cystic echinococcosis (CE) patients at an early stage is currently lacking. However, circulatory cell-free DNA (cfDNA) has shown potential as a biomarker for parasitic infections and could be used for diagnosing CE. Research Design and methods The plasma and urine samples were collected from 39 patients with confirmed CE through imaging and histopathological techniques. All plasma samples were tested for anti-echinococcal antibodies using a commercial ELISA test. Total plasma and urine cfDNA were extracted and an in-house PCR assay was developed to detect E. granulosus specific cfDNA in the samples of CE patients. Results Out of the 39 patients, 30 tested positive for E. granulosus using serology, with a sensitivity of 76.9%. Moreover, the detection rates for the cfDNA were 79.5% in plasma samples and 58.97% in urine samples using the 80 bp COX1 gene. The plasma-based PCR and serology test showed the highest agreement (Kappa = 0.53). Conclusions Plasma-based PCR has been found to be a reliable diagnostic tool for identifying CE patients at different cyst stages. It offers validity, speed, and sufficient sensitivity, making it an alternative to serology in diagnosing CE in endemic areas.
- 27 March 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-10
Detection of circulatory E. granulosus-derived cell-free DNA in the plasma and urine of human cystic echinococcosis using an in-house PCR: a potential promising diagnostic biomarker
Background The diagnostic tool for identifying cystic echinococcosis (CE) patients at an early stage is currently lacking. However, circulatory cell-free DNA (cfDNA) has shown potential as a biomarker for parasitic infections and could be used for diagnosing CE. Research Design and methods The plasma and urine samples were collected from 39 patients with confirmed CE through imaging and histopathological techniques. All plasma samples were tested for anti-echinococcal antibodies using a commercial ELISA test. Total plasma and urine cfDNA were extracted and an in-house PCR assay was developed to detect E. granulosus specific cfDNA in the samples of CE patients. Results Out of the 39 patients, 30 tested positive for E. granulosus using serology, with a sensitivity of 76.9%. Moreover, the detection rates for the cfDNA were 79.5% in plasma samples and 58.97% in urine samples using the 80 bp COX1 gene. The plasma-based PCR and serology test showed the highest agreement (Kappa = 0.53). Conclusions Plasma-based PCR has been found to be a reliable diagnostic tool for identifying CE patients at different cyst stages. It offers validity, speed, and sufficient sensitivity, making it an alternative to serology in diagnosing CE in endemic areas.
- Open Access
- 7 August 2023
- Published by MDPI AG in Preprints.org
Hepato-Renal Protective Potential of Dimethyl Fumarate in Alloxan-Induced Diabetic Mice Model by Modulating of Sirt1, Nrf2 and Inflammatory Genes Expressions
Background: Despite advances in diabetes-related treatments, the effects of the disease have not yet been adequately reversed or prevented in patients. Therefore, there is an urgent need to develop more effective medication-assisted treatments in this field. Methods: In this study, type 1 diabetes mice models was established using multiple low-dose alloxan, and the diabetic mice were treated with three doses of dimethyl fumarate (DMF) i.e low, medium, and high viz. 20, 40 and 80 mg/kg, respectively for a period of 21 days. Then, specific test were done to evaluate blood biochemical parameters, oxidative stress markers, inflammatory genes expression, and histopathological changes in the mice kidney and liver. Results: The obtained results showed remarkably improved anti-diabetic, hepato-renal-protective, and oxidative stress indexes of DMF in alloxan-induced diabetic mice (p< 0.001). Treated mice with DMF demonstrated a noteworthy decrease in blood glucose levels when compared with diabetic group (p< 0.001). Diabetic liver and kidney tissues showed marked dilation of bile ducts, tubules, infiltration, and inflammation. On the contrary, the histological features of the treated mice with DMF improve as shown by normal size of glomerular capillaries along with decrease in less dilatation of ducts in comparison with diabetic mice. The real-time quantitative PCR results indicated that DMF injection decreased the alloxan-induced increase of significant elevations in mRNA levels of pro-inflammatory cytokines and adhesion molecules such as TNF-α, IL-6, and NF-κB levels in both kidney and liver tissues. Meanwhile, mice treated with DMF showed an increase in Sirt1 and Nrf2 expression in comparison to diabetic group. Conclusion: In conclusion, it can be concluded that DMF treatment provides hepato-renal protective effects on alloxan-induced diabetic mice model by attenuating ROS inflammatory pathways. Keywords: Diabetes, Dimethyl fumarate, Alloxan, Anti-inflammatory responses, Hepato-renal-protective effects.
- 7 August 2023
- Published by MDPI AG in Preprints.org
Open AccessHepato-Renal Protective Potential of Dimethyl Fumarate in Alloxan-Induced Diabetic Mice Model by Modulating of Sirt1, Nrf2 and Inflammatory Genes Expressions
Background: Despite advances in diabetes-related treatments, the effects of the disease have not yet been adequately reversed or prevented in patients. Therefore, there is an urgent need to develop more effective medication-assisted treatments in this field. Methods: In this study, type 1 diabetes mice models was established using multiple low-dose alloxan, and the diabetic mice were treated with three doses of dimethyl fumarate (DMF) i.e low, medium, and high viz. 20, 40 and 80 mg/kg, respectively for a period of 21 days. Then, specific test were done to evaluate blood biochemical parameters, oxidative stress markers, inflammatory genes expression, and histopathological changes in the mice kidney and liver. Results: The obtained results showed remarkably improved anti-diabetic, hepato-renal-protective, and oxidative stress indexes of DMF in alloxan-induced diabetic mice (p< 0.001). Treated mice with DMF demonstrated a noteworthy decrease in blood glucose levels when compared with diabetic group (p< 0.001). Diabetic liver and kidney tissues showed marked dilation of bile ducts, tubules, infiltration, and inflammation. On the contrary, the histological features of the treated mice with DMF improve as shown by normal size of glomerular capillaries along with decrease in less dilatation of ducts in comparison with diabetic mice. The real-time quantitative PCR results indicated that DMF injection decreased the alloxan-induced increase of significant elevations in mRNA levels of pro-inflammatory cytokines and adhesion molecules such as TNF-α, IL-6, and NF-κB levels in both kidney and liver tissues. Meanwhile, mice treated with DMF showed an increase in Sirt1 and Nrf2 expression in comparison to diabetic group. Conclusion: In conclusion, it can be concluded that DMF treatment provides hepato-renal protective effects on alloxan-induced diabetic mice model by attenuating ROS inflammatory pathways. Keywords: Diabetes, Dimethyl fumarate, Alloxan, Anti-inflammatory responses, Hepato-renal-protective effects.
- 1 June 2023
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 23 (5) , 377-389
miR-638: A Promising Cancer Biomarker with Therapeutic Potential
Background: There is an unmet need to improve the diagnosis of cancer with precise treatment strategies. Therefore, more powerful diagnostic, prognostic, and therapeutic biomarkers are needed to overcome tumor cells. microRNAs (miRNAs, miRs), as a class of small non-coding RNAs, play essential roles in cancer through the tumor-suppressive or oncogenic effects by post-transcriptional regulation of their targets. Many studies have provided shreds of evidence on aberrantly expressed miRNAs in numerous cancers and have shown that miRNAs could play potential roles as diagnostic, prognostic, and even therapeutic biomarkers in patients with cancers. Findings have revealed that miR-638 over or underexpression might play a critical role in cancer initiation, development, and progression. However, the mechanistic effects of miR-638 on cancer cells are still controversial. Conclusion: In the present review, we have focused on the diagnostic, prognostic, and therapeutic potentials of miR-638 and discussed its mechanistic roles in various types of cancers.
- 1 June 2023
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 23 (5) , 377-389
miR-638: A Promising Cancer Biomarker with Therapeutic Potential
Background: There is an unmet need to improve the diagnosis of cancer with precise treatment strategies. Therefore, more powerful diagnostic, prognostic, and therapeutic biomarkers are needed to overcome tumor cells. microRNAs (miRNAs, miRs), as a class of small non-coding RNAs, play essential roles in cancer through the tumor-suppressive or oncogenic effects by post-transcriptional regulation of their targets. Many studies have provided shreds of evidence on aberrantly expressed miRNAs in numerous cancers and have shown that miRNAs could play potential roles as diagnostic, prognostic, and even therapeutic biomarkers in patients with cancers. Findings have revealed that miR-638 over or underexpression might play a critical role in cancer initiation, development, and progression. However, the mechanistic effects of miR-638 on cancer cells are still controversial. Conclusion: In the present review, we have focused on the diagnostic, prognostic, and therapeutic potentials of miR-638 and discussed its mechanistic roles in various types of cancers.
- Open Access
- 16 May 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 9 (2) , 39479
Galbanic acid of Ferula assa-foetida L, as a regulator of the AMPK pathway in reduction of lipid accumulation in HepG2 cells
Introduction: Hepatic fat accumulation is a complication of non-alcoholic fatty liver disease (NAFLD). An AMP-activated protein kinase (AMPK) reduces the synthesis of fatty acids by inhibiting sterol regulatory element-binding transcription factor 1-c (SREBP1-C) and acetyl COA carboxylase (ACC). Objectives: We aimed to investigate the impress of galbanic acid (Gal) from the Ferula plant on AMPK and its inhibitory effect on lipogenic enzymes in HepG2 cells. Materials and Methods: In an applied-fundamental study, HepG2 cells were treated for 24 hours with Gal in palmitate (Pal). Resveratrol (RSV) was conducted as a positive control. Fatty acid synthase (FAS) and SREBP1-C gene expression were evaluated by reverse transcription polymerase chain reaction (RT-PCR). FAS, phospho-acetyl-CoA carboxylase (P-ACC), P-AMPK, AMPK, SREBP-1c, and ACC protein levels were measured by western blotting. Lipid accumulation was investigated qualitatively and semi-quantitatively with oil red. Results: The semi-quantitative results of oil revealed a substantial reduction (P<0.004) in lipid accumulation for treatment with Gal. The significant increase in the protein level of P-AMPK (P<0.001) and P-ACC (P=0.054) and significant decrease in FAS (P<0.003), SREBP-1c (P<0.001) and ACC (P<0.011) due to the effect galbanic acid was observed. FAS gene expression decreased significantly (P<0.009), while the decrease in SREBP-1c gene expression was not significant (P=0.303). Conclusion: These findings direct that galbanic acid can be a new regulator of AMPK. Hence, the present study may introduce galbanic acid as a new plan to positively regulate the AMPK pathway, which leads to the regulation of various cellular processes.
- 16 May 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 9 (2) , 39479
Open AccessGalbanic acid of Ferula assa-foetida L, as a regulator of the AMPK pathway in reduction of lipid accumulation in HepG2 cells
Introduction: Hepatic fat accumulation is a complication of non-alcoholic fatty liver disease (NAFLD). An AMP-activated protein kinase (AMPK) reduces the synthesis of fatty acids by inhibiting sterol regulatory element-binding transcription factor 1-c (SREBP1-C) and acetyl COA carboxylase (ACC). Objectives: We aimed to investigate the impress of galbanic acid (Gal) from the Ferula plant on AMPK and its inhibitory effect on lipogenic enzymes in HepG2 cells. Materials and Methods: In an applied-fundamental study, HepG2 cells were treated for 24 hours with Gal in palmitate (Pal). Resveratrol (RSV) was conducted as a positive control. Fatty acid synthase (FAS) and SREBP1-C gene expression were evaluated by reverse transcription polymerase chain reaction (RT-PCR). FAS, phospho-acetyl-CoA carboxylase (P-ACC), P-AMPK, AMPK, SREBP-1c, and ACC protein levels were measured by western blotting. Lipid accumulation was investigated qualitatively and semi-quantitatively with oil red. Results: The semi-quantitative results of oil revealed a substantial reduction (P<0.004) in lipid accumulation for treatment with Gal. The significant increase in the protein level of P-AMPK (P<0.001) and P-ACC (P=0.054) and significant decrease in FAS (P<0.003), SREBP-1c (P<0.001) and ACC (P<0.011) due to the effect galbanic acid was observed. FAS gene expression decreased significantly (P<0.009), while the decrease in SREBP-1c gene expression was not significant (P=0.303). Conclusion: These findings direct that galbanic acid can be a new regulator of AMPK. Hence, the present study may introduce galbanic acid as a new plan to positively regulate the AMPK pathway, which leads to the regulation of various cellular processes.